{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-118097","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2025-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.772176+00:00","generated_at":"2026-05-16T14:53:17.677990+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort","bullets":["DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).","High-dose cohort achieved 100% complete response (CR) rate at Month 1 in evaluable patients.","Phase II expansion will evaluate EB103 in relapsed/refractory B-cell NHL at RP2D.","Majority of Phase I patients were high-risk, including one with CNS lymphoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-118097","json":"https://secwatch.observer/filing/0001213900-25-118097.json","markdown":"https://secwatch.observer/filing/0001213900-25-118097.md","text":"https://secwatch.observer/filing/0001213900-25-118097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025118097/0001213900-25-118097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025118097/ea0268496-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:53:17.677990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}